Figure 3.

Serial changes from baseline in pulmonary failure indexes and markers in peripheral blood in the survivor and non-survivor groups treated with PMX-DHP therapy. P/F ratio (a), SOFA score (b), CRP (c), LDH (d), KL-6 (e), and neutrophil counts in peripheral blood (f) in the survivor group (solid line and closed circles) and non-survivor group (dotted line and closed squares) among the patients after PMX-DHP therapy. There were significant differences in the serial changes in P/F ratio, the SOFA score, and blood neutrophil counts from initial treatment to day 5 between the two groups (p = 0.015, p < 0.001, p = 0.035, respectively), whereas serial changes in the serum levels of CRP (p = 0.119), LDH (p = 0.116), and KL-6 (p = 0.178) did not show significant differences between the groups. The data are expressed as means ± standard deviations. Comparisons of variables between groups over time were analyzed by repeated measures analysis of variance (ANOVA) adjusted for the baseline values as a covariate, and p-values between groups are illustrated. Additionally, the P/F ratio at day 5 and SOFA scores at days 3 and 5 in the survivor group are significantly better than those in the non-survivor group (*p < 0.01 compared with the non-survivor group). The neutrophil counts in the survivor group at day 3 after PMX-DHP therapy are significantly lower than those at the beginning of PMX-DHP therapy (#p < 0.001 compared with the beginning of PMX-DHP therapy).